Complete Omics Inc. (official website) – For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.

Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.

NEW YORK – Researchers at Johns Hopkins University have developed a targeted mass spec method for measuring cancer-linked neoantigens.

Described in a study published last month in Cancer Immunology Research, the method could prove useful both for studying tumor immunology and in the development of personalized cancer immunotherapies, said Qing Wang, first author on the paper and founder and CEO of clinical omics firm Complete Omics.

NEW YORK (GenomeWeb) – Researchers in the lab of Johns Hopkins University professor Bert Vogelstein have identified a pair of potential peptide biomarkers for ovarian cancer.

Described in a study published this week in Proceedings of the National Academy of Sciences, the markers stem from efforts by the lab, which had traditionally focused on cancer genomics, to move more seriously into the proteomic and protein biomarker space, said Qing Wang, a faculty member in Vogelstein’s lab and first author on the study.

The peptide markers were validated using a selected-reaction monitoring system developed by Wang and his colleagues that uses light-labeled peptides and extensive fractionation to enable highly sensitive and reproducible quantitation of candidate biomarkers in plasma.